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PLATELET activating factor (PAF) is a potent inflammatory
lipid. In this study we assessed the ability ofPAF to impact
lymphatic vessel function by altering prenodal lymphatic
resistance. Intralymphatic PAF (7.47 10 -6, 7.47 x 10-s
and 7.47 x 10-4 M) increased lymphatic perfusion pres-
sure at the two highest infusion rates. PAF mediated
lymphatic constriction was not altered by the intra-arterial
infusion of phentolamine but was blocked by the
intra-arterial infusion of the PAF receptor antagonist WEB
2170. These data indicate that in addition to PAF’s effects
on microvascular permeability, this agent may also impact
the ability of the lymphatics to transport fluid through
alterations in lymphatic smooth muscle tone. PAF
mediated lymphatic constriction is not mediated by
-receptors but rather through PAF receptor mediated
mechanism.
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Introduction
Platelet activating factor (PAF) was first
identified as a biological mediator when its release
was shown from sensitized rabbit basophils which
had been stimulated by antigen. This factor was
subsequently identified chemically as an acetyl
glyceryl ether of phosphotidylcholine which is
produced by leukocytes, macrophages, basophils
and platelets from a number of species (including
man) during anaphylactoid reactions. 2’3 PAF is a
potent anaphylactoid agent and its administration
in experimental animals results in cytopenia for
platelets and neutrophils, systemic hypotension,
platelet aggregation and degranulation, acute
respiratory distress and release of a number of
vasoactive compounds including histamine, sero-
tonin, slow reacting substance of anaphylaxis and
leukotriene B4. Evidence is also accumulating
which suggests that PAF may play an important
role in the inflammatory process. Vemulapalli eta].4
have shown that the intravenous administration of
bolus doses of PAF in the anaesthetized dog results
in marked decreases in plasma volume, indicating a
significant increase in vascular permeability and
transvascular fluid flux. Inarrea et al. have shown
that the infusion of immune aggregates in the
mouse induced an increase in vascular permeability
as evidenced by a nearly 25% reduction in blood
volume. The decrease in blood volume was closely
paralleled by the amount of PAF recovered from
the tissues. Furthermore, the study revealed that the
release of PAF preceded the increase in vascular
permeability. Bjork et al. have examined the effects
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of PAF on the microcirculation of the hamster
cheek pouch in situ. They reported that the topical
application of PAF caused constriction of small
arteries and an increase in vascular permeability at
the level of the postcapillary venule. We have
previously shown that the intra-arterial infusion of
PAF in the canine forelimb significantly increases
microvascular permeability as indicated by increases
in skin lymph flow and lymph protein concentra-
tion. 7 This action of PAF can be blocked by
pretreatment of the forelimb with the /2-receptor
agonist terbutaline.
We have previously established that a number of
endogenous vasoactive agents including adrenaline,
noradrenaline, dopamine, prostanoids, putative
inflammatory mediators and endothelin are capable
of constricting prenodal lymph vessels in the canine
forelimb,s<2 In the current study, we assessed the
ability of platelet activating factor to alter
transvascular fluid flux by impacting the lymphatic
system through alterations in lymphatic vessel
resistance. In addition, we have assessed the
involvement of lymphatic o-receptors and PAF
receptors in the observed PAF mediated lymphatic
constriction.
Materials and Methods
Adult mongrel dogs of either sex were
anaesthetized with sodium pentobarbital (35 mg/kg
i.v. and supplemented as needed), intubated and
ventilated with room air. Small incisions were made
in the skin of the right forelimb and the brachial
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artery, a small side branch of the brachial artery and
a skin small vein and artery in the paw were
isolated. The forelimb was perfused at constant
arterial inflow via the brachial artery with blood
obtained from a cannulated femoral artery.
Forelimb perfusion pressure was measured from the
side branch of the brachial artery and skin small
vein and artery pressures were measured on the
dorsal and ventral surfaces of the paw respectively.
Systemic arterial pressure was measured by
inserting a catheter into the brachial artery and
advancing it into the aorta. A catheter was inserted
into the left external jugular vein and advanced to
the level of the right atrium for measurement of
central venous pressure. A prenodal lymph vessel
was cannulated in the direction of normal lymph
flow with a PE 10 catheter. The lymph vessel was
perfused at constant flow at a volume flow rate of
0.034 ml/min with a perfusate which was the
supernatant of a 1:1 mixture of autologous
arterial blood and heparinized Krebs solution.
Lymphatic perfusion pressure was measured from
the perfusion system at a point upstream to the
point of cannulation of the prenodal lymph ves-
sel. A three-way stopcock, which had been modified
such that all three ports were confluent, allowed for
measurement of lymphatic perfusion pressure
and for the lymphatic to be perfused with either
control perfusate or perfusate containing PAF.
8
The protocol was as follows: in all experiments,
the lymph vessel was perfused with control
perfusate for a minimum of 15 min to ensure that
all measured pressures had reached steady state
values. The lymph vessel was then perfused with a
perfusate containing platelet activating factor in a
concentration of 7.47 10
-6 7.47 x 10
-5 or
7.47 10-4M for a minimum of 15 min or until
the peak response was obtained. The lymph vessel
was then again perfused with control perfusate until
all measured pressures returned to control values.
Preliminary experiments with PAF indicated that
the initial infusion significantly attenuated the
effects seen with any subsequent infusion in the
same animal, a trait that PAF shares with
angiotensin II, histamine and neurokinin A, and
thus the three dosages were tested in three separate
series of animals to reveal the true potency of PAF
as a lymphatic constrictor.
In the PAF and receptor antagonist experiments,
following acquisition of control values, an
intra-arterial infusion of phentolamine (400 #g/min)
or WEB 2170 (4/g/min) was begun. After 10 min
of phentolamine infusion or 15 min of WEB 2170
infusion, PAF was infused intralymphatically at a
concentration of 7.47 104 M and the infusion was
continued for 15 min. The lymphatic was then
infused with control perfusate until all measured
pressures returned to control values.
All drugs were made up freshly daily in norrnal
saline. Phentolamine mesylate and WEB 2170 were
infused via a needle tipped catheter into the arterial
supply to the forelimb with the use of a pressure
independent infusion pump. The final dilutions of
PAF from the stock solution were made by adding
control perfusate such that the osmolarity and
protein concentration of the final solution approx-
imated normal lymph.
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All data were analysed with Student’s t-test as
modified for paired replicates. Pressures obtained
immediately prior to beginning a manoeuvre were
compared with the peak responses observed during
that manoeuvre. A probability of _<0.05 was
considered statistically significant.
Results
The intralymphatic infusion of PAF at
7.47 x 10
-6 7.47 x 10 -s and 7.47 x 10-4M re-
suited in significant increases in lymphatic perfusion
pressure at the two higher dosages (Fig. 1).
Lymphatic perfusion pressure in approximately
half of the animals was increased by the lowest
dosage of PAF utilized but variability in the
response prevented the small increase seen at this
dosage from being statistically significant. These
data indicate that the threshold dosage for
significant lymphatic constriction with intralympha-
tic PAF is very near 7.47 10
-6 M. It should be
remembered that these data were derived from three
separate series of animals and therefore the
differences in the control lymphatic perfusion
pressures seen in Fig. 1 do not reflect an instability
of the preparation with time but rather modest
differences in control lymphatic resistance between
different groups of animals. The intralymphatic
infusion ofPAF did not significantly affect systemic,
forelimb perfusion, skin small artery, skin small
vein or central venous pressures (Table 1) at any of
the infusion rates employed in this study.
PEAK
EZZ2Z] CONTROL
747 10-6M 747 10-5M 747 IO-M
FIG. 1. The effects of the intralymphatic infusion of PAF on lymphatic
perfusion pressure, n 8, 8 and 9 in three separate groups of animals.
p _< 0.05, paired
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Table 1. Effect of intralymphatic PAF infusion on vascular pressures, n 8, 8 and 9 in each
of three separate groups
7.47 x 10-6 7.47 x 10-5 7.47 x 10-4
C P C P C P
SYS 131 _+ 4.8 131 4- 4.5 131 + 4.8 129 _+ 5.6 123 _+ 4.6 122 + 4.5
PERF 117 +_ 4.7 117 +_ 4.8 115 +_ 4.7 115 +_ 5.8 121 +_ 6.3 123 4- 7.3
SSA 85 4- 6.5 87 _+ 6.3 85 _+ 5.6 85 4- 6.4 93 _+ 7.8 96 + 8.5
SSV 9 4- 0.8 9 _+ 0.8 11 _+ 0.8 11 4- 0.9 10 4- 0.5 10 +_ 0.5
CV 4 4- 0.2 4 _+ 0.2 4 _+ 0.4 4 _+ 0.4 4 _+ 0.5 3 4- 0.4
SYS mean systemic, PERF forelimb perfusion, SSA skin small artery, SSV skin small
vein, CV central venous. All pressures are means 4- standard error of the mean expressed in
mmHg. p _< 0.05 Student’s paired t. C control, P peak pressure.
The infusion of phentolamine intra-arterially at
400/g/min did not significantly alter lymphatic
perfusion pressure from its control value of
6.5 +_ 1.2 mmHg (Fig. 2). As expected, phentola-
mine infusion did significantly decrease mean
systemic arterial pressure and forelimb arterial
pressures. Skin small vein pressure and central
venous pressure were not significantly affected by
phentolamine infusion (Table 2). The subsequent
intralymphatic infusion of PAF at 7.47 10-4M
significantly increased lymphatic perfusion pressure
from a control value of 6.7 q- 1.3 mmHg to a peak
PEAK
CONTROL
Phentolamne PAF 47 10 M
FIG. 2. The effects of intralymphatic PAF infusion during the intra-arterial
infusion of phentolamine, n 6. p _< 0.05, paired
Table 2. Effect of intralymphatic PAF infusion during the intra-
arterial infusion of phentolamine on vascular pressures
Phentolamine PAF
400/g/min 7.47 x 10-4 molar
C P C P
SYS 125 -I- 2.6 117* __+ 1.9 116 -t- 2.3 105" -!- 2.7
PERF 114 + 3.9 91" + 1.3 91 1.5 87 + 1.2
SSA 80 + 7.3 58* + 4.6 57 + 5.0 53 + 4.5
SSV 10 + 0.6 10 + 0.6 10 + 0.6 10 + 0.6
CV 4 4- 0.4 4 4- 0.4 4 -I- 0.3 4 _+ 0.3
SYS mean systemic, PERF- forelimb perfusion, SSA- skin
small artery, SSV- skin small vein, CV central venous. All
pressures are means 4- standard error of the mean expressed in
mmHg. p <_ 0.05 Student’s paired t. C control, P peak
pressure.
pressure of 11.0+ 1.9mmHg (Fig. 2). This
response is essentially identical to that seen with this
dosage of PAF in the absence of 0-receptor
blockade (Fig. 1) and indicates that PAF mediated
lymphatic constriction does not involve lymphatic
0-receptors. We have previously shown that
infusion of phentolamine at this dosage is capable
of completely blocking either adrenaline or
noradrenaline mediated lymphatic constriction.
The intralymphatic infusion of PAF during
phentolamine infusion did not significantly aEect
vascular pressures (Table 2).
Intra-arterial infusion of the PAF receptor
antagonist WEB 2170 at 4/g/min does not
significantly alter lymphatic perfusion pressure (Fig.
3) nor does it significantly affect vascular pressures
(Table 3). The subsequent intralymphatic infusion
ofPAF during the continued infusion ofWEB 2170
was not able to significantly alter the lymphatic
perfusion pressure (Fig. 3). As before, intralympha-
tic PAF did not alter vascular pressures (Table 3).
Discussion
It has been reported previously that a wide array
of endogenous vasoactive agents are capable of
constricting prenodal lymphatic vessels in the
PEAK
CONTROL
WEB 2170 PAF 7.47 x 10 -4 M
FIG. 3. The effects of intralymphatic PAF infusion during the intra-arterial
infusion of the PAF receptor antagonist WEB 2170. n 6. p < 0.05,
paired
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Table 3. Effects of intralymphatic PAF infusion during the
intra-arterial infusion of WEB 2170 on vascular pressures
WEB 2170 PAF
4 #g/min 7.47 x 10-4 molar
C P C P
SYS 130 +_ 5.7 130 _+ 6.0 130 +_ 6.0 131 _+ 4.6
PERF 117 + 6.3 120 +_ 5.9 120 _+ 5.9 126 __+ 4.8
SSA 83 _+ 9.2 86 _+ 10 86 _+ 10 91 _+ 8.3
SSV 8 _+ 0.4 8 _+ 0.4 8 _+ 0.4 8 -I- 0.5
CV 4 _+ 0.2 4 _+ 0.2 4 _+ 0.2 4 _+ 0.2
SYS mean systemic, PERF forelimb perfusion, SSA skin
small artery, SSV skin small vein, CV central venous. All
pressures are means -i- standard error of the mean expressed in
mmHg. p < 0.05 Student’s paired t. C control, P peak
pressure.
canine forelimb. These agents include the catechol-
amines (adrenaline, noradrenaline and dopamine),
endothelin, prostanoids, acetylcholine, bradykinin,
histamine, serotonin and neurokinin A.
8-13 The
results of the current study clearly demonstrate that
PAF is likewise a member of the pool of
endogenous vasoactive agents which can cause
prenodal lymphatic constriction. Previous work has
revealed that the threshold concentrations of these
agents which are required to produce lymphatic
constriction varies from the extremely potent
endothelin (10-1-10
-9 M) to markedly less potent
agents such as prostaglandin E1 and arachidonic
acid (10-4-10-3 M). The results of the current
experiments indicate that the threshold concentra-
tion of intralymphatic PAF is very near the lowest
dosage used (7.47 x 10
-6 M). Although the in-
crease in lymphatic perfusion pressure seen with
this dosage is not statistically different when viewed
as a mean of eight animals, lymphatic perfusion
pressure did increase in five of the eight animals.
Thus it would appear that PAF is a moderately
potent constrictor of lymphatic vessels with a
threshold concentration similar to that of prosta-
glandin F2a or the al-receptor agonist phenyl-
ephrine and the a2-receptor agonist a-methylnor-
epinephrine.’4
In the PAF and phentolamine experiments, the
intralymphatic infusion of PAF during phentola-
mine resulted in an increase in lymphatic perfusion
pressure which was not different from that which
was seen with this same dosage of PAF in the
non-a-receptor blocked preparation (Fig. 1). It has
previously been shown14 that the intra-arterial
infusion of phentolamine at this dosage is capable
of completely blocking either adrenaline or
noradrenaline mediated lymphatic constriction.
Therefore, this data would indicate that the
lymphatic constriction produced by the in-
tralymphatic administration ofPAF is not mediated
through lymphatic a-receptors although it has
already been shown that the prenodal lymphatic
vessels of the canine forelimb contain both al- and
14 a2-receptors.
The intralymphatic infusion of PAF during the
intra-arterial infusion of the specific PAF receptor
antagonist WEB 217015-1v did not result in any
significant alterations in lymphatic perfusion
pressure. These data therefore indicate that the
lymphatic constriction produced by PAF is
mediated through lymphatic PAF receptor mechan-
isms. These data are in agreement with previous
work indicating the effectiveness of specific PAF
receptor antagonists in blocking PAF mediated
vascular and cellular (platelet and neutrophil
aggregation) actions. Felix et al.8 showed that an
intracoronary infusion of the PAF antagonist WEB
2086 antagonized PAF mediated coronary constric-
tion in a dose-dependent manner. Ma et al.
15
reported that WEB 2170 inhibited the coronary
constriction and tissue injury associated with
coronary occlusion and reperfusion in a feline
model. Klee et al.6 demonstrated that WEB 2170
significantly inhibited the formation of micro-
embolisms of rat platelets induced by platelet
activating factor, whereas Heuerv reported that
WEB 2170 inhibited PAF induced aggregation of
human platelets in vitro but did not significantly
affect the aggregation of platelets produced by
ADP, adrenaline, serotonin, collagen or arachidonic
acid. Additionally, he showed that WEB 2170
inhibited PAF induced platelet aggregation in the
guinea-pig in vivo. Furthermore, the pretreatment of
guinea-pigs with WEB 2170 either orally or
intravenously completely protected the animals
from the bronchoconstriction and systemic hypo-
tension produced by intravenous infusion of PAF.
In this respect, WEB 2170 displayed a significantly
greater potency than WEB 2086. Thus WEB 2170
appears to be a highly specific and potent PAF
receptor antagonist. The results of the current study
indicate that the intra-arterial infusion ofWEB 2170
is capable of completely blocking PAF mediated
lymphatic constriction. These results suggest that
the prenodal lymphatic vessels of the canine
forelimb contain PAF receptors and it is through
PAF receptor mechanisms that PAF produces
increases in lymphatic smooth muscle tone.
Platelet activating factor has been implicated as
a participant in a number of pathophysiological
conditions including anaphylaxis, inflammation and
oedema formation. It has been established that PAF
increases microvascular permeability and transvas-
cular fluid flux in a number of experimental models.
In the canine forelimb, the increase in microvascular
permeability seen in the skin circulation can be
blocked by the intra-arterial infusion of the
fl2-receptor agonist terbutaline. In this respect,
PAF shares a commonality with histamine and
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bradykinin whose ability to increase microvasvcular
permeability in the canine forelimb is likewise
blocked by terbutaline pretreatment. Of interest,
histamine, bradykinin and now PAF have also been
shown to possess the ability to constrict prenodal
lymphatic vessels, thus affecting the ability of these
vessels to transport fluid. PAF appears to be more
potent than either histamine or bradykinin in
producing lymphatic constriction.
11 Thus it would
appear that a variety of agents can impact fluid
balance through interactions with the microvascular
membrane to alter its permiselectivity and can also
impact the ability of the lymphatic system to
transport fluid back to the vasculature.
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